PharmaNet Development Group, Inc. to Announce First Quarter 2007 Financial Results on May 3, 2007
13 April 2007 - 10:05AM
Business Wire
PharmaNet Development Group, Inc. (NASDAQ: PDGI), a leading
provider of drug development services, today announced that it will
release its first quarter 2007 financial results on Thursday, May
3, 2007 before the market opens. Following the pre-market release,
the Company plans to host a conference call and webcast to review
these results at 8:30 a.m. EDT. First Quarter 2007 Earnings
Conference Call: When: Thursday, May 3, 2007 at 8:30 a.m. EDT
Dial-in: (888) 396-2386 for U.S. (617) 847-8712 for International
Pass code: 40038227 Dial-in Replay: (888) 286-8010 for U.S. (617)
801-6888 for International Pass code: 83884265 Available
approximately two hours after the call through Thursday, May 10,
2007 Webcast: Please visit www.pharmanet.com and select the
investor tab to access the webcast or access the link directly at
http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=124176
&eventID=1523683. (Due to its length, this URL may need to be
copied/pasted into your Internet browser's address field.��Remove
the extra space if one exists.) The archived webcast will be
available for approximately thirty (30) days following the
conference call. About PharmaNet Development Group, Inc. PharmaNet
Development Group, a global drug development company, provides a
comprehensive range of services to the pharmaceutical,
biotechnology, generic drug, and medical device industries. The
Company offers clinical-development solutions including early and
late stage consulting services, Phase l clinical studies and
bioanalytical analyses, and Phase Il, III and IV clinical
development programs. With approximately 2,200 employees and more
than 35 facilities throughout the world, PharmaNet is a recognized
leader in outsourced clinical development. For more information,
please visit our website at www.pharmanet.com. Forward-Looking
Statements Certain statements made in this press release are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 (the "Act"). Additionally,
words such as "seek," "intend," "believe," "plan," "estimate,"
"expect," "anticipate" and other similar expressions are
forward-looking statements within the meaning of the Act. Some or
all of the results anticipated by these forward-looking statements
may not occur. Factors that could cause or contribute to such
differences include, but are not limited to, industry trends and
information; the Company's ability to determine its impairment
charges and costs of discontinued operations; whether the Company
will achieve its estimated value relating to discontinued
operations; developments with respect to the SEC's inquiry and
securities class action lawsuits and derivative lawsuits; the
Company�s ability to successfully achieve and manage the technical
requirements of specialized clinical trial services, while
complying with applicable rules and regulations; regulatory
changes; changes affecting the clinical research industry; a
reduction of outsourcing by pharmaceutical and biotechnology
companies; the Company�s ability to compete internationally in
attracting clients in order to develop additional business; the
Company�s evaluation of its backlog and the potential cancellation
of contracts; its ability to retain and recruit new employees; its
clients' ability to provide the drugs and medical devices used in
its clinical trials; the Company�s future stock price; the
Company�s assessment of its effective tax rate and tax allowance;
the Company�s financial guidance; the Company�s future effective
tax rate; the Company�s anticipated capital expenditures; the
Company�s costs associated with compliance of Section 404 of the
Sarbanes-Oxley Act; the impact on the Company of foreign currency
transaction costs and the effectiveness of any hedging strategies
that it implements; and the national and international economic
climate as it affects drug development operations. Further
information can be found in the Company�s risk factors contained in
its Annual Report on Form 10-K for the year ended December 31, 2006
and its most recent Quarterly Report on Form 10-Q. The Company does
not undertake to update the disclosures made herein, and you are
urged to read our filings with the Securities and Exchange
Commission.
Pharmanet Development Grp (MM) (NASDAQ:PDGI)
Historical Stock Chart
From Jul 2024 to Jul 2024
Pharmanet Development Grp (MM) (NASDAQ:PDGI)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Pharmanet Development Grp (MM) (NASDAQ): 0 recent articles
More PharmaNet Development Group, Inc. News Articles